Financials

v2.4.1.9
Consolidated Balance Sheets (USD $)
Dec. 31, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 3,103,969us-gaap_CashAndCashEquivalentsAtCarryingValue $ 10,048,466us-gaap_CashAndCashEquivalentsAtCarryingValue
Short-term investments   305,538us-gaap_HeldToMaturitySecuritiesCurrent
Accounts receivable 267,199us-gaap_AccountsReceivableNetCurrent 458,391us-gaap_AccountsReceivableNetCurrent
Other current assets 174,179us-gaap_OtherAssetsCurrent 344,386us-gaap_OtherAssetsCurrent
Total current assets 3,545,347us-gaap_AssetsCurrent 11,156,781us-gaap_AssetsCurrent
Equipment, net 244,537us-gaap_PropertyPlantAndEquipmentNet 457,912us-gaap_PropertyPlantAndEquipmentNet
Restricted cash 1,699,759us-gaap_RestrictedCashAndCashEquivalentsNoncurrent 2,921,724us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
Other long-term assets 56,131us-gaap_OtherAssetsNoncurrent 159,224us-gaap_OtherAssetsNoncurrent
Investment in Incuron, LLC 4,268,458us-gaap_EquityMethodInvestments  
Total assets 9,814,232us-gaap_Assets 14,695,641us-gaap_Assets
Current liabilities:    
Accounts payable 1,057,743us-gaap_AccountsPayableCurrent 794,397us-gaap_AccountsPayableCurrent
Accrued expenses 1,804,456us-gaap_AccruedLiabilitiesCurrent 2,445,446us-gaap_AccruedLiabilitiesCurrent
Deferred revenue 156,317us-gaap_DeferredRevenueCurrent 1,069,438us-gaap_DeferredRevenueCurrent
Accrued warrant liability 862,074us-gaap_DerivativeLiabilitiesCurrent 1,241,311us-gaap_DerivativeLiabilitiesCurrent
Current portion of notes payable 2,640,968us-gaap_NotesPayableCurrent 351,527us-gaap_NotesPayableCurrent
Current portion of capital lease obligation 7,522us-gaap_CapitalLeaseObligationsCurrent 83,634us-gaap_CapitalLeaseObligationsCurrent
Total current liabilities 6,529,080us-gaap_LiabilitiesCurrent 5,985,753us-gaap_LiabilitiesCurrent
Noncurrent portion of capital lease obligation   7,522us-gaap_CapitalLeaseObligationsNoncurrent
Long-term debt 1,499,050us-gaap_LongTermDebt 7,121,388us-gaap_LongTermDebt
Commitments and contingencies      
Total liabilities 8,028,130us-gaap_Liabilities 13,114,663us-gaap_Liabilities
Stockholders' equity:    
Additional paid-in capital 132,693,988us-gaap_AdditionalPaidInCapital 125,723,083us-gaap_AdditionalPaidInCapital
Other comprehensive income/(loss) (380,110)us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax 307,339us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax
Accumulated deficit (133,935,562)us-gaap_RetainedEarningsAccumulatedDeficit (135,564,666)us-gaap_RetainedEarningsAccumulatedDeficit
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2014 and 2013, respectively      
Common stock, $.005 par value; 160,000,000 shares authorized, 2,858,126 and 2,259,818 shares issued and outstanding as of December 31, 2014 and 2013, respectively 14,287us-gaap_CommonStockValue 11,299us-gaap_CommonStockValue
Total Cleveland BioLabs, Inc. stockholders' equity (deficit) (1,607,397)us-gaap_StockholdersEquity (9,522,945)us-gaap_StockholdersEquity
Noncontrolling interest in stockholders' equity 3,393,499us-gaap_MinorityInterest 11,103,923us-gaap_MinorityInterest
Total stockholders' equity 1,786,102us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest 1,580,978us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
Total liabilities and stockholders' equity $ 9,814,232us-gaap_LiabilitiesAndStockholdersEquity $ 14,695,641us-gaap_LiabilitiesAndStockholdersEquity
v2.4.1.9
Consolidated Statements of Operations (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Revenues:      
Grants and contracts $ 3,701,899us-gaap_ContractsRevenue $ 8,487,966us-gaap_ContractsRevenue $ 3,570,710us-gaap_ContractsRevenue
Operating expenses:      
Research and development 9,654,144us-gaap_ResearchAndDevelopmentExpense 19,525,950us-gaap_ResearchAndDevelopmentExpense 22,501,805us-gaap_ResearchAndDevelopmentExpense
General and administrative 8,469,690us-gaap_GeneralAndAdministrativeExpense 12,038,775us-gaap_GeneralAndAdministrativeExpense 11,115,511us-gaap_GeneralAndAdministrativeExpense
Total operating expenses 18,123,834us-gaap_OperatingExpenses 31,564,725us-gaap_OperatingExpenses 33,617,316us-gaap_OperatingExpenses
Loss from operations (14,421,935)us-gaap_OperatingIncomeLoss (23,076,759)us-gaap_OperatingIncomeLoss (30,046,606)us-gaap_OperatingIncomeLoss
Other income (expense):      
Interest and other income (expense) (1,089,582)us-gaap_OtherNonoperatingIncomeExpense 44,925us-gaap_OtherNonoperatingIncomeExpense 295,123us-gaap_OtherNonoperatingIncomeExpense
Foreign exchange gain (loss) (1,036,459)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax 38,202us-gaap_ForeignCurrencyTransactionGainLossBeforeTax (365,138)us-gaap_ForeignCurrencyTransactionGainLossBeforeTax
Gain on deconsolidation of Incuron, LLC 14,206,555us-gaap_DeconsolidationGainOrLossAmount    
Change in value of warrant liability 2,662,329us-gaap_FairValueAdjustmentOfWarrants 2,864,348us-gaap_FairValueAdjustmentOfWarrants 7,701,981us-gaap_FairValueAdjustmentOfWarrants
Equity in loss of Incuron, LLC (285,542)us-gaap_IncomeLossFromEquityMethodInvestments    
Total other income 14,457,301us-gaap_NonoperatingIncomeExpense 2,947,475us-gaap_NonoperatingIncomeExpense 7,631,966us-gaap_NonoperatingIncomeExpense
Net income (loss) 35,366us-gaap_ProfitLoss (20,129,284)us-gaap_ProfitLoss (22,414,640)us-gaap_ProfitLoss
Net loss attributable to noncontrolling interests 1,593,738us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 2,866,407us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 4,180,498us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net income (loss) attributable to Cleveland BioLabs, Inc. $ 1,629,104us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (17,262,877)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (18,234,142)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Net income (loss) available to common stockholders per share of common stock, basic and diluted $ 0.60us-gaap_EarningsPerShareBasicAndDiluted $ (7.67)us-gaap_EarningsPerShareBasicAndDiluted $ (9.75)us-gaap_EarningsPerShareBasicAndDiluted
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted 2,702,884us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 2,250,142us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 1,869,443us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
v2.4.1.9
Consolidated Statements of Cash Flows (USD $)
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Cash flows from operating activities:      
Net income (loss) $ 35,366us-gaap_ProfitLoss $ (20,129,284)us-gaap_ProfitLoss $ (22,414,640)us-gaap_ProfitLoss
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Depreciation 200,792us-gaap_Depreciation 376,213us-gaap_Depreciation 479,595us-gaap_Depreciation
Amortization of loan costs 640,248us-gaap_AdjustmentForAmortization 94,995us-gaap_AdjustmentForAmortization  
Unrealized currency loss on short-term investments     52,726us-gaap_UnrealizedGainLossOnInvestments
(Gain) loss on equipment disposal 24,685us-gaap_GainLossOnSaleOfPropertyPlantEquipment (3,222)us-gaap_GainLossOnSaleOfPropertyPlantEquipment 18,997us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Impairment loss on property and equipment   293,162us-gaap_ImpairmentOfLongLivedAssetsHeldForUse  
Noncash compensation 496,470us-gaap_AllocatedShareBasedCompensationExpense 1,473,449us-gaap_AllocatedShareBasedCompensationExpense 2,535,217us-gaap_AllocatedShareBasedCompensationExpense
Warrant issuance costs 171,116cbli_WarrantIssuanceCosts   244,857cbli_WarrantIssuanceCosts
Equity in loss of Incuron, LLC 285,542us-gaap_IncomeLossFromEquityMethodInvestments    
Change in value of warrant liability (2,662,329)us-gaap_FairValueAdjustmentOfWarrants (2,864,348)us-gaap_FairValueAdjustmentOfWarrants (7,701,981)us-gaap_FairValueAdjustmentOfWarrants
Gain on deconsolidation of Incuron, LLC (14,206,555)us-gaap_DeconsolidationGainOrLossAmount    
Changes in operating assets and liabilities:      
Accounts receivable 629,397us-gaap_IncreaseDecreaseInAccountsReceivable (416,495)us-gaap_IncreaseDecreaseInAccountsReceivable 1,736,199us-gaap_IncreaseDecreaseInAccountsReceivable
Other current assets (1,242)us-gaap_IncreaseDecreaseInOtherCurrentAssets 697,966us-gaap_IncreaseDecreaseInOtherCurrentAssets (182,428)us-gaap_IncreaseDecreaseInOtherCurrentAssets
Other long-term assets 15,690us-gaap_IncreaseDecreaseInOtherNoncurrentAssets (29,732)us-gaap_IncreaseDecreaseInOtherNoncurrentAssets (6,414)us-gaap_IncreaseDecreaseInOtherNoncurrentAssets
Accounts payable 459,337us-gaap_IncreaseDecreaseInAccountsPayable (713,502)us-gaap_IncreaseDecreaseInAccountsPayable 609,522us-gaap_IncreaseDecreaseInAccountsPayable
Deferred revenue (756,808)us-gaap_IncreaseDecreaseInDeferredRevenue (2,062,332)us-gaap_IncreaseDecreaseInDeferredRevenue 3,238,124us-gaap_IncreaseDecreaseInDeferredRevenue
Accrued expenses 213,104us-gaap_IncreaseDecreaseInAccruedLiabilities 180,483us-gaap_IncreaseDecreaseInAccruedLiabilities 740,723us-gaap_IncreaseDecreaseInAccruedLiabilities
Net cash used in operating activities (14,455,187)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (23,102,647)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (20,649,503)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:      
Purchase of short-term investments (1,408,169)us-gaap_PaymentsToAcquireHeldToMaturitySecurities   (5,220,781)us-gaap_PaymentsToAcquireHeldToMaturitySecurities
Sale of short-term investments 1,689,670us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities 2,197,940us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities 8,312,120us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities
Purchase of equipment (20,222)us-gaap_PaymentsToAcquireMachineryAndEquipment (139,491)us-gaap_PaymentsToAcquireMachineryAndEquipment (178,271)us-gaap_PaymentsToAcquireMachineryAndEquipment
Cash divested upon deconsolidation of Incuron, LLC (2,048,023)us-gaap_CashDivestedFromDeconsolidation    
Increase in restricted cash   (1,497,740)us-gaap_IncreaseInRestrictedCash (1,541,366)us-gaap_IncreaseInRestrictedCash
Net cash provided by (used in)investing activities (1,786,744)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 560,709us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations 1,371,702us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:      
Issuance of common stock, net of offering costs 9,697,501us-gaap_ProceedsFromIssuanceOfCommonStock   15,675,727us-gaap_ProceedsFromIssuanceOfCommonStock
Net proceeds/(repayment) of long-term debt (4,176,275)us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities 7,327,675us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities  
Noncontrolling interest capital contribution to Incuron, LLC 5,152,438us-gaap_ProceedsFromMinorityShareholders   5,893,557us-gaap_ProceedsFromMinorityShareholders
Exercise of options   12,392us-gaap_ProceedsFromStockOptionsExercised 2,375us-gaap_ProceedsFromStockOptionsExercised
Repayment of capital lease obligation (83,634)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (78,125)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations (52,410)us-gaap_RepaymentsOfLongTermCapitalLeaseObligations
Net cash provided by financing activities 10,590,030us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 7,261,942us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 21,519,249us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Effect of exchange rate change on cash and equivalents (1,292,595)us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents (323,621)us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents 538,046us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents
Decrease in cash and cash equivalents (6,944,497)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (15,603,617)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 2,779,494us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 10,048,466us-gaap_CashAndCashEquivalentsAtCarryingValue 25,652,083us-gaap_CashAndCashEquivalentsAtCarryingValue 22,872,589us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 3,103,969us-gaap_CashAndCashEquivalentsAtCarryingValue 10,048,466us-gaap_CashAndCashEquivalentsAtCarryingValue 25,652,083us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of cash flow information:      
Cash paid during the period for interest 451,327us-gaap_InterestPaid 17,105us-gaap_InterestPaid 23,708us-gaap_InterestPaid
Supplemental schedule of noncash financing activities:      
Noncash warrant issuance costs 15,993cbli_NoncashWarrantIssuanceCostsOnCommonStockOffering 117,999cbli_NoncashWarrantIssuanceCostsOnCommonStockOffering  
Equipment acquired through lease financing     221,690us-gaap_CapitalLeaseObligationsIncurred
Warrants [Member]      
Supplemental schedule of noncash financing activities:      
Allocation of equity proceeds to fair value of warrants $ 2,216,593us-gaap_StockIssued1
/ us-gaap_FinancialInstrumentAxis
= us-gaap_WarrantMember
   
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue